Arix Bioscience (ARIX) Ord
Share news, reports & tips
20 May 2020 10:24
(Sharecast News) - Venture capital company Arix Bioscience noted on Wednesday that its portfolio company, Amplyx Pharmaceuticals, has closed a $53m (£43.22m) series C extension.
10 March 2020 11:49
(Sharecast News) - Biotechnology venture capital company Arix Bioscience reported a year-end net asset value of ?202m in its annual results on Tuesday, or 149p per share, equating to a 25% decline in net...
17 February 2020 10:21
(Sharecast News) - Biotechnology investor Arix Bioscience announced on Monday that one of its portfolio companies, Imara, has filed a registration statement with the United States Securities and Exchange...
2 October 2019 08:53
(Sharecast News) - Biotechnology-focussed venture capital company Arix Bioscience announced the departure of its chief financial officer James Rawlingson on Wednesday.
26 September 2018 13:59
(Sharecast News) - Healthcare and life science company Arix Bioscience announced on Wednesday that one of its group businesses, genome editing company LogicBio Therapeutics, has filed a registration...
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2021. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.